Published in Health Business Week, May 14th, 2004
"We are pleased to open the ownership of our Company to a broader group of investors," said Andrew J. Whelan, CEO of BioElectronics Corporation. "We have a broad and deep pipeline of innovative therapeutic devices."
The company's first U.S. Food & Drug Administration (FDA) cleared product, ActiPatch Therapy is a dermal patch with an embedded microchip that delivers weeks of continuous pulsed electromagnetic energy. ActiPatch Therapy is the miniaturized equivalent of the large pulsed electromagnetic energy machines prescribed by physicians for decades to reduce...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.